Adicet Bio to Present Phase 1 Prula-cel Data in Lupus on September 28
Adicet Bio will report Phase 1 clinical data for prula-cel in patients with systemic lupus erythematosus, with or without lupus nephritis, on September 28, 2026. The company will host a webcast at 8:00 a.m. ET to discuss the results. Adicet is developing allogeneic gamma delta CAR-T and in vivo CAR-T therapies.
Adicet Bio, a Redwood City, California-based clinical-stage company traded as ACET, plans to release Phase 1 results for prulacabtagene leucel, or prula-cel, in systemic lupus erythematosus patients, including those with lupus nephritis. The update is scheduled for Monday, September 28, 2026.
The company will follow the disclosure with an 8:00 a.m. ET webcast. A replay is expected on Adicet’s investor site about two hours later and will remain accessible for 30 days. Adicet’s pipeline includes allogeneic gamma delta CAR-T and in vivo CAR-T programs aimed at autoimmune diseases, blood cancers, and solid tumors.
If results are encouraging, they may influence how researchers and clinicians view off-the-shelf cell therapies for autoimmune disease, potentially expanding options for patients whose lupus is difficult to control. Investors and biotech watchers could react to safety and efficacy signals, affecting funding for similar programs. However, Phase 1 data are early and may not predict later outcomes.